PT  - JOURNAL ARTICLE
AU  - Logesvar Balaguru
AU  - Chen Dun
AU  - Andrea Meyer
AU  - Sanuri Hennayake
AU  - Christi M. Walsh
AU  - Christopher Kung
AU  - Brittany Cary
AU  - Frank Migliarese, Jr.
AU  - Tinglong Dai
AU  - Ge Bai
AU  - Kathleen Sutcliffe
AU  - Martin A. Makary
TI  - NIH Funding of COVID-19 Research in 2020: a Cross Sectional Study
AID  - 10.1101/2021.12.08.21267482
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.12.08.21267482
4099  - http://medrxiv.org/content/early/2021/12/11/2021.12.08.21267482.short
4100  - http://medrxiv.org/content/early/2021/12/11/2021.12.08.21267482.full
AB  - Objective This study aims to characterize and evaluate the NIH’s grant allocation pattern of COVID-19 research.Design Cross sectional studySetting COVID-19 NIH RePORTER Dataset was used to identify COVID-19 relevant grants.Participants 1,108 grants allocated to COVID-19 research.Main Outcomes and Measures The primary outcome was to determine the number of grants and funding amount the NIH allocated for COVID-19 by research type and clinical/scientific area. The secondary outcome was to calculate the time from the funding opportunity announcement to the award notice date.Results The NIH awarded a total of 56,169 grants in 2020, of which 2.0% (n=1,108) were allocated for COVID-19 research. The NIH had a $42 billion budget that year, of which 5.3% ($2.2 billion) was allocated to COVID-19 research. The most common clinical/scientific areas were social determinants of health (n=278, 8.5% of COVID-19 funding), immunology (n=211, 25.8%), and pharmaceutical interventions research (n=208, 47.6%). There were 104 grants studying COVID-19 non-pharmaceutical interventions, of which 2 grants studied the efficacy of face masks and 6 studied the efficacy of social distancing. Of the 83 COVID-19 funded grants on transmission, 5 were awarded to study airborne transmission of COVID-19, and 2 grants on transmission of COVID-19 in schools. The average time from the funding opportunity announcement to the award notice date was 151 days (SD: ±57.9).Conclusion In the first year of the pandemic, the NIH diverted a small fraction of its budget to COVID-19 research. Future health emergencies will require research funding to pivot in a timely fashion and funding levels to be proportional to the anticipated burden of disease in the population.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any funding Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors